| First Author | Wang YY | Year | 2015 |
| Journal | Oncotarget | Volume | 6 |
| Issue | 19 | Pages | 17016-30 |
| PubMed ID | 26219259 | Mgi Jnum | J:309232 |
| Mgi Id | MGI:6757345 | Doi | 10.18632/oncotarget.4849 |
| Citation | Wang YY, et al. (2015) Deletion of Smad3 improves cardiac allograft rejection in mice. Oncotarget 6(19):17016-30 |
| abstractText | T cells play a critical role in acute allograft rejection. TGF-beta/Smad3 signaling is a key pathway in regulating T cell development. We report here that Smad3 is a key transcriptional factor of TGF-beta signaling that differentially regulates T cell immune responses in a mouse model of cardiac allograft rejection in which donor hearts from BALB/c mice were transplanted into Smad3 knockout (KO) and wild type (WT) mice. Results showed that the cardiac allograft survival was prolonged in Smad3 KO recipients. This allograft protection was associated with a significant inhibition of proinflammatory cytokines (IL-1beta, TNF-alpha, and MCP-1) and infiltration of neutrophils, CD3+ T cells, and F4/80+ macrophages. Importantly, deletion of Smad3 markedly suppressed T-bet and IFN-gamma while enhancing GATA3 and IL-4 expression, resulting in a shift from the Th1 to Th2 immune responses. Furthermore, mice lacking Smad3 were also protected from the Th17-mediated cardiac injury, although the regulatory T cell (Treg) response was also suppressed. In conclusion, Smad3 is an immune regulator in T cell-mediated cardiac allograft rejection. Loss of Smad3 results in a shift from Th1 to Th2 but suppressing Th17 immune responses. Thus, modulation of TGF-beta/Smad3 signaling may be a novel therapy for acute allograft rejection. |
